A to Z / Metabolic / weight loss
Mazdutide
Also known as IBI362, LY3305677.
Best known for The dual agonist developed primarily in China
Evidence★★☆☆☆
Safety dataPoorly characterised
Route Weekly injection
United StatesNot approved
AustraliaNot approved
as at 16 September 2026
What it is
Mazdutide is a GLP-1 and glucagon receptor dual agonist, based on the natural hormone oxyntomodulin. Its development has been led in China, where it has progressed furthest, with phase-3 trials completed there. It is not approved in Australia or the United States.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Tirzepatide, Retatrutide, Survodutide, Semaglutide
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Mazdutide. It is not medical advice and not a recommendation to use it.